Table 4.
Consumption in DDD/100BD and DDD/patient by class of antibiotics for systemic use (ATC: J01) in the three clinical wards at TASH during the one-year study period (n = 1645)
| Class of antibiotics | ATC Code | Antibiotic consumption | |||||
|---|---|---|---|---|---|---|---|
| Internal Medicine | Gynecology/Obstetrics | Surgery | |||||
| DDD/100BD | DDD/patient | DDD/100BD | DDD/Patient | DDD/100BD | DDD/patient | ||
| Third-generation cephalosporins | J01DD | 33.1 | 9.1 | 10.6 | 1.7 | 38.5 | 5.8 |
| Fluoroquinolones | J01MA | 11.4 | 3.1 | 1.8 | 0.3 | 1.9 | 0.3 |
| Imidazole derivatives | J01XD | 11.3 | 3.1 | 7.2 | 1.1 | 16.3 | 2.5 |
| Glycopeptides | J01XA | 8.9 | 2.4 | 1.1 | 0.2 | 5.2 | 0.8 |
| Sulfonamides and trimethoprim | J01EE | 7.8 | 2.1 | 0.9 | 0.1 | 0.2 | – |
| Macrolides | J01FA | 5.5 | 1.5 | 3.4 | 0.5 | 0.3 | 0.1 |
| Penicillins with extended spectrum | J01CA | 4.1 | 1.1 | 16.3 | 2.6 | 1.5 | 0.2 |
| Fourth-generation cephalosporins | J01DE | 3.1 | 0.9 | – | – | 1.3 | 0.2 |
| Penicillins plus beta-lactamase inhibitors | J01CR | 2.0 | 0.5 | 0.5 | 0.1 | 1.0 | 0.2 |
| Beta-lactamase-sensitive penicillins | J01 CE | 1.6 | 0.4 | 0.7 | 0.1 | – | |
| Other aminoglycosides | J01GB | 0.9 | 0.2 | 1.3 | 0.2 | 0.8 | 0.1 |
| Lincosamides | J01FF | 0.6 | 0.1 | – | – | 0.3 | 0.1 |
| Beta-lactamase-resistant penicillins | J01CF | 0.6 | 0.2 | 0.4 | 0.1 | 4.0 | 0.6 |
| Tetracyclines | J01AA | 0.3 | 0.1 | 2.3 | 0.4 | – | – |
| Carbapenems | J01DH | 0.2 | – | – | – | – | – |
| First-generation cephalosporins | J01DB | 0.2 | 0.1 | 1.1 | 0.2 | 0.2 | – |
| Streptomycins | J01GA | 0.1 | – | – | – | – | |
| Amphenicols | J01BA | 0.1 | – | – | – | 0.1 | – |
| Total | J01 | 91.8 | 24.8 | 47.6 | 7.6 | 71.6 | 10.9 |